Samuel J. Reich appointed CEO of SAB Biotherapeutics; remains Executive Chairman

SAB Biotherapeutics, Inc.

Reich expands role from Executive Chairman to CEO effective February 2, 2024.
Co-founder Eddie J. Sullivan continues as President and board member, leading operations and R&D.
Reich co-founded Biscayne Neurotherapeutics (sold to Supernus) and Acuity Pharmaceuticals.
Company advancing lead candidate SAB-142 for delaying type 1 diabetes progression.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Samuel J. Reich

Chief Executive Officer

SABS · SAB Biotherapeutics, Inc.

Effective: 2024-01-30
Filed: February 2, 2024, 6:59 PM ET

On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Samuel J. Reich was appointed as Chief Executive Officer at SAB Biotherapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.

View on SEC.gov

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-010093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.